跳至主要内容
临床试验/NCT05756621
NCT05756621已完成不适用

SUPER-refractory Status Epilepticus After Cardiac Arrest: a Multicenter, Retrospective, Cohort Study of Dual Anti-glutamate Therapy With Ketamine and Perampanel

University of Milano Bicocca18 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2022年1月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
84
试验地点
18
主要终点
Number of patients with resolution of status epilepticus

研究概览

简要总结

Status epilepticus (SE) is found in 20-30% of patients in coma after cardiac arrest, is often refractory to medical therapy and is considered a negative prognostic factor. Intensity and duration of treatment of refractory and super-refractory post-anoxic SE pose the ethical dilemma between futility of treatments and, conversely, their premature suspension. A recent study by the Epilepsy Center of the San Gerardo Hospital has shown that patients with super-refractory post-anoxic SE and favorable prognostic indicators can achieve a good functional outcome in more than 40% of cases, if treated with intensive and protracted therapy.

However, there is profound uncertainty about the best combination of antiseizure medications and anesthetics to use in this condition. A combined anti-glutamatergic therapy with ketamine (anti-NMDA receptor) and perampanel (anti-AMPA receptor), aimed at counteracting the excitotoxicity linked to global cerebral ischemia, could be particularly effective in the treatment of super-refractory SE with post-anoxic etiology. Preliminary results in the first 26 patients treated in the Coordinating Center of the project indicate that this therapy appears safe and highly effective (80% SE resolution, 40% good neurological outcome).

The aim of the SUPER-CAT study is to investigate the efficacy and safety of combined therapy with ketamine and perampanel (dual anti-glutamatergic therapy) in patients with post-anoxic super-refractory status epilepticus, compared to other therapies, using a multi-centre, retrospective, cohort study design.

详细描述

Status epilepticus (SE) is found in 20-30% of patients in a coma after cardiac arrest, is frequently refractory to medical therapy and is usually considered a poor prognostic factor. The intensity and duration of treatment for post-anoxic refractory and super-refractory SE remains a highly controversial issue, posing the ethical dilemma between futility and premature discontinuation of care.

Although the TELSTAR randomized clinical trial demonstrated the futility of aggressive treatment in post-anoxic patients with generalized periodic pattern, the question remains open about the benefit of aggressive therapy in post-anoxic patients with SE properly defined according to the Salzburg criteria.

The latest guidelines of the European Resuscitation Council recommend the use of electroencephalogram (EEG) both for the neurological prognosis and for the diagnosis of post-cardiac arrest epileptic seizures, define the highly malignant EEG patterns (which do not include status epilepticus; while generalized periodic pattern and suppressed background are included) and recommend treatment of seizures with first-line antiepileptic therapy (levetiracetam or valproate), while there are no recommendations regarding second-line antiepileptic therapy. The same guidelines recommend a multi-modal approach, using different indicators (brainstem reflexes, somatosensory evoked potentials, EEG patterns, neuron-specific enolase [NSE] levels and neuroimaging) to arrive at the formulation of the neurological prognosis. A favorable neurological outcome is present in <15% of post-anoxic SE cases after moderate intensity treatment.

A recent study by the Epilepsy Center of the San Gerardo Hospital ASST Monza on a prospective cohort of 166 consecutive patients with cardiac arrest showed that patients with refractory post-anoxic SE and favorable prognostic indicators can achieve a good functional outcome (CPC 1-2) in > 40% of cases, if treated aggressively and prolonged with second-line anti-epileptic and anesthetic therapy.

However, there is profound uncertainty about the best combination of antiseizure medications and anesthetics to use in this condition. A pilot study of the Epilepsy Center of the San Gerardo ASST Monza hospital has shown an efficacy of 75% of anti-glutamatergic therapy with oral load of perampanel (anti-AMPA receptor), combined with different types of anesthetics (including ketamine, anti -NMDA receptor), in 8 patients with super-refractory post-anoxic SE. All patients included in this series presented the main favorable prognostic indicators (presence of brainstem reflexes, presence of N20 cortical evoked potentials, absence of generalized periodic pattern) and in 60% of cases (5 out of 8 cases) a neuroimaging with mild anoxic damage. The clinical outcome was favorable, with the achievement of functional independence in 50% of cases (4 cases out of 8) after 3 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age ≥ 18 years
  • patients in coma after cardio-circulatory arrest (CCA) admitted to the Intensive Care Unit and treated with target temperature management (TTM) for the first 24 hours
  • initiation of continuous electroencephalographic (cEEG) monitoring within 24-36 hours of CCA
  • diagnosis of super-refractory status epilepticus, relapsed after the first cycle of anesthetics (lasting > 24 hours) and antiepileptic therapy, defined according to the international Salzburg criteria9
  • presence of pupillary reflex present bilaterally
  • presence of N20 cortical response present bilaterally

排除标准

  • EEG with periodic pattern (generalized periodic discharges; GPDs)
  • status epilepticus resolved after the first cycle of anesthetics + antiepileptics
  • pregnant women

研究组 & 干预措施

Control (OTHERS)

Patients who received any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs ketamine and perampanel.

干预措施: Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel (Drug)

Dual anti-glutamate therapy (DUAL)

Patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of "ketamine pattern") + oral perampanel via nasogastric tube for 5 days (12 mg if weight > 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight < 50 kg), followed by gradual dose reduction according to clinical evolution.

干预措施: Ketamine (Drug)

结局指标

主要结局

Number of patients with resolution of status epilepticus

时间窗: Over the entire period of stay in the Intensive Care Unit (up to 30 days)

Number of patients with resolution of status epilepticus, not followed by relapse and without the use of additional antiepileptic drugs, evaluated over the entire period of stay in the Intensive Care Unit, in the two groups DUAL versus OTHERS

次要结局

  • Number of patients with with time-locked resolution of status epilepticus(first 5 days after start of therapy)
  • Number of patients with early favorable neurological outcome(Over the entire period of stay in the Intensive Care Unit (up to 30 days))
  • Number of patients with favorable long-term neurological outcome(6 months after cardiac arrest)
  • mortality in intensive care(Over the entire period of stay in the Intensive Care Unit (up to 30 days))
  • mortality at 6 months(6 months after cardiac arrest)
  • cumulative probability of resolution of status epilepticus(Over the entire period of stay in the Intensive Care Unit (up to 30 days))
  • Number of patients with abnormal cholestasis indices(Over the entire period of stay in the Intensive Care Unit (up to 30 days))
  • Number of patients with third degree atrioventricular block or cardiac arrest recurrence(Over the entire period of stay in the Intensive Care Unit (up to 30 days))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验